This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
GAR1 / H/ACA ribonucleoprotein complex subunit 1 · IHC design guide
Design Immunohistochemistry for GAR1
Plan chromogenic GAR1 IHC in paraffin sections using the observed nuclear tissue pattern (HPA tissue IHC). Start with the catalog antibody’s 2–5 μg/ml IHC range (datasheet A07049-1), and compare high-staining bone marrow hematopoietic cells with adipose tissue adipocytes reported as undetected (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
GAR1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear staining observed in tissue (HPA tissue IHC) | |
| Staining pattern | Widespread nuclear staining across tissues (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A07049-1) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | Adipose tissue |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation conditions consistent across sections. (standard IHC practice; not target-specific) | |
| Caveat | Adipocytes stain high in breast but are undetected in adipose tissue (HPA tissue IHC) | |
| Regulation | Low tissue specificity (HPA tissue RNA) | |
| Isoform / epitope | 2 isoforms; assess epitope coverage for each (UniProt) |
Section 1
Recommended GAR1 IHC & IF Protocols
The catalog antibody’s IHC-P protocol (datasheet A07049-1) is accompanied by a published protocol for paraffin-embedded HCC tissue (PMC8541795).
| Sample | Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet A07049-1) |
| Fixation | Image fixative and duration unreported (datasheet A07049-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A07049-1); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A07049-1) |
| Primary antibody | Rabbit anti-GAR1, 2-5 μg/ml (datasheet A07049-1) |
| Primary incubation | Overnight at 4 °C (datasheet A07049-1) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A07049-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | GAR1-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: Ubiquitous nuclear expression. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA retrieval at pH 8.0 (datasheet A07049-1); the published HCC excerpt does not specify retrieval conditions (PMC8541795).
Section 2
What Is the Expected GAR1 Staining Pattern?
GAR1 is a nuclear protein concentrated in nucleoli and also found in Cajal bodies (UniProt Q9NY12). In paraffin-section IHC, expect nuclear staining across many cell types; HPA describes ubiquitous nuclear expression, with high staining in several listed tissues (HPA tissue IHC). HPA rates the tissue pattern Supported, with medium consistency between antibody staining and RNA expression (HPA tissue IHC). GAR1 has no transmembrane segment (UniProt Q9NY12 topology).
| Nuclear chromogen in glandular cells of appendix, adrenal gland, or cervix. | This fits the reported high staining in those cell populations and the ubiquitous nuclear profile (HPA tissue IHC). Assess the nuclei within each named population; neighboring cells need not have identical intensity (general IHC interpretation). |
| Nuclear staining with more intense punctate areas. | A nucleolar emphasis is biologically plausible because UniProt places GAR1 in nucleoli (UniProt Q9NY12). Routine chromogenic sections may not resolve nucleolar substructures; HPA's fibrillar-center assignment comes from ICC-IF (HPA subcellular). |
| Predominantly cytoplasmic, membranous, or extracellular staining, with little nuclear signal. | That distribution conflicts with GAR1's nuclear localization and lack of a transmembrane segment (UniProt Q9NY12). Treat it as suspect staining; inspect controls and detection conditions before assigning a biological explanation (general IHC practice). |
| Strong staining in an unexpected cell population, including adipocytes in adipose tissue. | HPA reports adipocytes as not detected in adipose tissue, yet high in breast; location therefore matters (HPA tissue IHC). Check morphology and controls for cross-reactivity or endogenous detection activity before calling the result GAR1-positive (general IHC practice). |
| No nuclear signal in a section expected to provide a positive comparison. | Bone-marrow hematopoietic cells and bronchial respiratory epithelium are listed as high (HPA tissue IHC). An absent result there weakens interpretation of a test section; review tissue integrity, controls, retrieval, and detection as general IHC checks. |
💡Expected GAR1 appearanceCall a result positive when nuclei in an HPA-listed high-staining cell population show convincing chromogen, potentially with nucleolar emphasis (HPA tissue IHC; UniProt Q9NY12); isolated cytoplasmic or extracellular color is suspect (UniProt Q9NY12; general IHC interpretation).
| Tissue and cell context | HPA reports low tissue RNA specificity and ubiquitous nuclear protein expression, but individual listed cell populations differ: several are High, while adipocytes in adipose tissue are Not detected (HPA tissue IHC). Compare the same cell population and tissue context. |
| Antibody evidence | The listed rabbit polyclonal antibody HPA059098 has Supported IHC status (HPA antibodies). HPA rates the overall tissue pattern Supported, with medium antibody-staining/RNA consistency (HPA tissue IHC); these labels support comparison, not certainty for every cell. |
| Compartment and topology | Nucleolus and Cajal-body localization, together with no transmembrane segment, favor an intranuclear reading (UniProt Q9NY12). The record gives no basis for interpreting a membrane outline as expected GAR1 staining. |
| Isoforms and processing | UniProt lists two isoforms and a 1–217 chain, with no signal peptide or propeptide (UniProt Q9NY12). No antibody epitope is supplied, so isoform-specific staining cannot be predicted from this record. |
| IF/ICC: where should signal appear? | HPA reports a supported nucleoli fibrillar-center location and an uncertain nucleoplasm location in ICC-IF images from A-431, PC-3, and U2OS (HPA subcellular). These IF details help interpret localization; they do not define an IHC protocol. |
| Situation | Likely cause | Next action |
|---|---|---|
| A listed high-staining tissue has no nuclear chromogen. | The result conflicts with that cell population's HPA IHC pattern (HPA tissue IHC); the immediate cause is undetermined. | Confirm the expected cells are present, then review the IHC-validated antibody, retrieval, primary incubation, and detection controls (general IHC practice). |
| Color appears mainly outside nuclei. | That compartment conflicts with the reported nuclear localization (UniProt Q9NY12); nonspecific staining or a detection artifact is possible (general IHC interpretation). | Compare a no-primary control and an HPA-listed positive tissue; adjust general blocking or detection conditions if the controls implicate background (general IHC practice). |
| Chromogen is diffuse across tissue or obscures nuclear boundaries. | Broad background limits compartment assessment; excess detection signal or inadequate blocking may contribute (general IHC practice). | Inspect the no-primary control, reduce overly strong detection or primary concentration, and preserve a counterstain that leaves nuclei readable (general IHC practice). |
| Adipocytes in adipose tissue stain strongly. | HPA lists them as Not detected there, although breast adipocytes are High (HPA tissue IHC); tissue context prevents a universal adipocyte rule. | Verify tissue identity and cell morphology; compare a no-primary control and nuclear staining in an HPA-listed positive population (general IHC practice; HPA tissue IHC). |
| Only weak nuclear color is visible in a listed High population. | HPA's High category describes its reported staining, not a guaranteed intensity in every preparation (HPA tissue IHC); the cause of weak color remains unresolved. | Check section quality and positive controls, then review retrieval and detection settings using standard IHC optimization (general IHC practice). |
| Puncta cannot be assigned confidently to nucleoli. | UniProt places GAR1 in nucleoli, but HPA's fibrillar-center detail was observed by ICC-IF (UniProt Q9NY12; HPA subcellular). Chromogenic resolution may be insufficient (general microscopy practice). | Score convincing nuclear staining at the resolution available; reserve the finer subnuclear call for the separate IF/ICC assessment (general microscopy practice). |
Experiment evidence
IHC & IF images showing GAR1 staining
A07049-1 · IHCIHC analysis of NOLA1/GAR1 using anti-NOLA1/GAR1 antibody (A07049-1). NOLA1/GAR1 was detected in a paraffin-embedded section of human breast
A07049-1 · IHCIHC analysis of NOLA1/GAR1 using anti-NOLA1/GAR1 antibody (A07049-1). NOLA1/GAR1 was detected in a paraffin-embedded section of human gastri
A07049-1 · IFIF analysis of NOLA1/GAR1 using anti-NOLA1/GAR1 antibody (A07049-1). NOLA1/GAR1 was detected in an immunocytochemical section of MCF-7 cells
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000109534-GAR1/tissue/cerebral+cortex#imid_16447667
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000109534-GAR1/tissue/colon#imid_16447601
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000109534-GAR1/tissue/liver#imid_16447586
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000109534-GAR1/tissue/kidney#imid_16447603
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA059098; green = GAR1, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA059098; green = GAR1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for GAR1 IHC & IF
🧪Run bone marrow first: hematopoietic cells should stain (HPA: High in bone marrow hematopoietic cells). Use adipose tissue as the negative tissue (HPA: adipocytes Not detected); on the positive slide, mature erythrocytes, if present, should lack nuclear staining because they have no nucleus (standard histology), but no nucleated internal negative population is established by the supplied HPA rows.
Positive control tissue: Adrenal gland (Glandular cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show GAR1 in A-431, PC-3, U2OS, with annotated localisation: Nucleoplasm (uncertain), Nucleoli fibrillar center (supported) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control and a matched rabbit IgG isotype control (caption: rabbit primary antibody); use GAR1 knockout material, if available, as a biological specificity control. Quench endogenous peroxidase in bone marrow and check for endogenous biotin with the avidin–biotin detection method (caption: SABC with DAB; standard IHC practice).
⚠️Feasibility: The selected A07049-1 tissue-IHC caption does not report a fixative, and the supplied evidence reports no GAR1-specific fixation window or fixation effect. The demonstrated paraffin-section procedure used heat retrieval in EDTA at pH 8.0 before primary antibody incubation at 2 μg/ml (caption); its reliance on retrieval has not been tested against an unretrieved section in the supplied evidence. Relative ease of frozen-section IHC or IF is unreported; interpret the adipose control cautiously because adipocytes are Not detected in adipose tissue yet High in breast (HPA: tissue rows).
HPA tissue IHC evidence for GAR1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Breast | Adipocytes | High | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced GAR1 IHC Tips
Troubleshoot GAR1 staining in paraffin sections by assessing retrieval, nuclear localisation, background and scoring; the IF guidance addresses the separate secondary application (datasheet A07049-1; UniProt Q9NY12).
How should I troubleshoot weak GAR1 staining after antigen retrieval?
Start with heat-mediated retrieval in EDTA at pH 8.0 for paraffin sections (datasheet A07049-1). The selected tissue image used 2 μg/mL primary antibody overnight at 4°C, giving a starting point while retrieval is evaluated (datasheet A07049-1). If nuclear staining remains weak, compare heat exposure and then consider citrate at pH 6.0 as a fallback, using matched sections and identical detection conditions (standard IHC practice). Judge improvement by clearer nucleolar signal within intact nuclei, since GAR1 is nucleolar and nuclear; discard conditions that produce broad tissue haze or damaged morphology (UniProt Q9NY12 localisation; standard IHC practice).
Can fixation explain inconsistent GAR1 staining between paraffin blocks?
The selected paraffin-section caption does not state a fixative, so GAR1-specific fixation sensitivity is unknown (datasheet A07049-1). Record the fixative, fixation interval and processing history for each block before attributing differences to the antibody (standard IHC practice). Compare blocks using the same EDTA pH 8.0 retrieval, primary concentration and detection run to limit technical variation (datasheet A07049-1; standard IHC practice). Evaluate nuclear detail and preservation alongside signal, because poor morphology can make focal nucleolar staining difficult to score (UniProt Q9NY12 localisation; standard IHC practice). Neither the tissue-expression profile nor the absence of a transmembrane segment establishes a preferred fixative for GAR1 (HPA tissue IHC; UniProt Q9NY12 topology).
Which staining pattern should count as GAR1 positive in IHC?
Prioritise staining within nuclei, especially discrete nucleolar staining, when assessing GAR1 in paraffin sections (UniProt Q9NY12 localisation). Nucleoplasmic staining can occur, although its assignment is uncertain in the subcellular record; the nucleoli fibrillar center assignment is supported (HPA subcellular). GAR1 is also reported in Cajal bodies, so a small intranuclear focus is biologically plausible but cannot be identified as a Cajal body by chromogenic staining alone (UniProt Q9NY12 localisation; standard IHC practice). Inspect a counterstained section at higher magnification to distinguish intranuclear signal from adjacent cytoplasm or pigment, and use the same compartment rule throughout scoring (standard IHC practice).
Can isoforms or epitope accessibility change how GAR1 stains?
GAR1 has 2 annotated isoforms, but the supplied antibody caption does not identify their recognised epitope or establish isoform selectivity (UniProt Q9NY12 isoforms; datasheet A07049-1). Treat a staining difference as an epitope-accessibility question before calling it isoform-specific expression (standard IHC practice). Keep EDTA at pH 8.0 and compare matched sections under controlled retrieval conditions to assess whether accessibility changes the nuclear signal (datasheet A07049-1; standard IHC practice). The record lists no transmembrane segment, glycosylation sites or annotated modified residues, but those annotations do not locate this antibody’s epitope or validate an isoform-specific IHC result (UniProt Q9NY12 topology and modifications; standard IHC practice).
How should I investigate GAR1 localisation by multiplex IF?
For IF/ICC, expect nuclear and nucleolar GAR1 signal, with possible Cajal body localisation (UniProt Q9NY12 localisation). Pair GAR1 with a validated marker for the cell population under study, such as glandular cells in a relevant specimen, and verify that the marker and GAR1 channels remain separable (HPA tissue IHC: glandular cells; standard IF practice). Choose spectrally separated fluorophores and assess unstained tissue autofluorescence before assigning a weak nuclear signal; a longer-wavelength channel may help when background is strongest at shorter wavelengths (standard IF practice). Because GAR1 has no transmembrane segment and is intranuclear, permeabilise sufficiently for antibody access to nuclei, then check that nucleolar structure remains intact (UniProt Q9NY12 topology and localisation; standard IF practice).
What should I check when GAR1 IHC has diffuse brown background?
First compare a no-primary control with the stained section to identify signal from the detection system or endogenous tissue activity (standard IHC practice). The selected example used biotinylated secondary antibody, streptavidin–biotin detection and DAB, so investigate background at each of those steps in the same workflow (datasheet A07049-1; standard IHC practice). Apply a peroxidase block and review biotin-related background controls as general chromogenic IHC measures, then compare matched sections before changing the primary concentration (standard IHC practice). The example used 10% goat serum blocking and 2 μg/mL primary antibody; diffuse cytoplasmic colour without convincing nuclear structure warrants caution (datasheet A07049-1; UniProt Q9NY12 localisation; standard IHC practice).
How should I score GAR1 across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define positivity in the nuclear compartment before scoring, and record nucleolar and broader nuclear patterns separately when they can be resolved (UniProt Q9NY12 localisation; standard IHC practice). An H-score combines staining intensity and the percentage of positive cells; alternatively, report the percentage of positive nuclei or positive-cell density per mm² (standard IHC practice). Normalise counts to the number of evaluable nuclei or the measured viable tissue area, and apply the same threshold to all sections (standard IHC practice). Stratify by the cell population being compared, because GAR1 staining is described as ubiquitous nuclear expression and a whole-section average may obscure population differences (HPA tissue IHC; standard IHC practice).
How can I distinguish true GAR1 staining from section artefacts?
A credible GAR1 result follows intact nuclei and can include nucleolar enrichment, consistent with its recorded localisation (UniProt Q9NY12 localisation; standard IHC practice). Check the cell population explicitly: the tissue profile reports high staining in several populations but no detection in adipose-tissue adipocytes, so cell identity and tissue context matter (HPA tissue IHC). Treat staining confined to cut edges or necrotic areas as suspect, and compare adjacent preserved areas under the same detection conditions (standard IHC practice). If brown signal persists without primary antibody, investigate endogenous peroxidase or detection-reagent background before interpreting it as GAR1 (standard IHC practice). The tissue IHC evidence is rated supported with medium RNA–staining consistency, which calls for controlled interpretation of discordant patterns (HPA tissue IHC).
Boster reagents
Best GAR1 / H/ACA ribonucleoprotein complex subunit 1 IHC Antibodies
A07049-1 has IHC images from human paraffin sections and an IF/ICC image from MCF-7 cells (catalog image captions); listed reactivity is human (catalog: reactivity).
Real IHC data
Anti-NOLA1/GAR1 Antibody ®
Cat # A07049-1
A07049-1 has IHC images from human breast cancer, gastric carcinoma, liver cancer, and ovarian adenoma paraffin sections (catalog: IHC image captions). A07049-1 also has an IF/ICC image from MCF-7 cells (catalog: IF image caption).
Which to pick: For tissue IHC, choose A07049-1 for human paraffin sections; its captions do not report the fixative (catalog: IHC image captions). For IF/ICC, A07049-1 has an MCF-7 image and a listed concentration of 5 μg/ml (catalog: IF image caption; datasheet: IF dilution). No cross-species option is supported: A07049-1 lists human reactivity only, and its clonality is unspecified (catalog: reactivity; clone field).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q9NY12 (GAR1_HUMAN, H/ACA ribonucleoprotein complex subunit 1).
- Human Protein Atlas. GAR1 tissue IHC expression (reliability: Supported).
- Human Protein Atlas. GAR1 subcellular location (ICC-IF): Localized to the nucleoplasm and nucleoli fibrillar center..
- Human Protein Atlas. GAR1 antibody validation summary (1 antibodies).
- Relevance of 2'-O-Methylation and Pseudouridylation for the Malignant Melanoma. Cancers 2021 — PMC7963185.
- H/ACA snoRNP Gene Family as Diagnostic and Prognostic Biomarkers for Hepatocellular Carcinoma. Pharmacogenomics and personalized medicine 2021 — PMC8541795.
- PubMed PMID:10757788 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
- PubMed PMID:11509230 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for GAR1 (H/ACA ribonucleoprotein complex subunit 1). Expected localisation Nuclear staining observed in tissue (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A07049-1). Validated IHC antibody: A07049-1 at 2-5 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet A07049-1); 2. Fixation: Image fixative and duration unreported (datasheet A07049-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A07049-1); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A07049-1); 8. Primary antibody: Rabbit anti-GAR1, 2-5 μg/ml (datasheet A07049-1); 9. Primary incubation: Overnight at 4 °C (datasheet A07049-1). Watch for: Fixation: Keep fixation conditions consistent across sections. (standard IHC practice; not target-specific); Caveat: Adipocytes stain high in breast but are undetected in adipose tissue (HPA tissue IHC); Isoform / epitope: 2 isoforms; assess epitope coverage for each (UniProt); Regulation: Low tissue specificity (HPA tissue RNA). Evidence: UniProt Q9NY12, HPA tissue IHC · Supported, HPA ICC-IF · nucleoplasm and nucleoli fibrillar center., Datasheet A07049-1, PMC8541795. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/GAR1/immunohistochemistry-ihc-guide.